Conjunctive Administration of Intravenous Heparin Attenuates Cross-linked Fibrin Degradation in Patients Treated with Streptokinase

Summary

Increases in thrombin activity occur in patients treated with streptokinase, but conjunctive therapy with intravenous heparin does not appear to improve either the rate of early infarct artery patency or survival in patients with acute myocardial infarction. In a recent study we found that concentrations of fibrinopeptide A, a marker of thrombin-mediated fibrin formation, were lower in the first 3 h in patients treated with intravenous heparin (5000 U bolus followed by a fixed-dose 1000 U/h infusion, n = 14) compared with subcutaneous (12,500 U every 12 h, started 4 h after streptokinase, n = 14) administration, but were increased in both groups of patients, consistent with persistent thrombin activity. To determine whether the differential effects of the intensity of heparinization on thrombin formation were reflected in differences in fibrin degradation, we measured cross-linked fibrin degradation products (XL-FDP) before and 1,2,3,8,12, and 24 h after streptokinase in the same cohort of patients, with a new ELISA with a D-dimer-specific capture antibody (MAb 3B6) and a fibrin-specific tag antibody (MAb 1D2, Agen, Brisbane, Australia). The incidence of early coronary recanalization assessed by creatine-kinase MM isoforms (increase in activity ≥0.18%/min), was similar in both groups (79 vs 86%). Concentrations of XL-FDP were similar in patients with and without recanalization, but were lower in patients treated with intravenous compared with subcutaneous heparin at 8 h, but the results did not reach statistical significance (627 ±151 ng/ml versus 1007 ± 157 ng/ ml, p = 0.06), and were significantly lower at 12 h (327 ± 72 versus 781 ± 162 ng/ml, p = 0.03 at 12 h) (mean ± SEM). Concentrations of cross-linked fibrin degradation products were also lower in patients in whom the activated partial thromboplastin time was greater than two times the control, compared with those with inadequate anticoagulation (498 ± 105 versus 1084 ± 179 ng/ml; p = 0.02) (mean ± SEM). Thus, more effective inhibition of thrombin with conjunctive intravenous heparin therapy results in less cross-linked fibrin turnover in the first 12 h after thrombolysis with streptokinase. This probably reflects decreased fibrin formation with therapeutic anticoagulation.

• References

• 1 Ridker PM, Hebert PR, Hennekens CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?. Lancet 1993; 341: 1574-1577
• 2 Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopep-tide A: Evidence for continued thrombosis despite intensive fibrinolysis. J Am Coll Cardiol 1987; 10: 527-529
• 3 Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol 1994; 24: 1445-1552
• 4 The GUSTO angiographic investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622
• 5 The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
• 6 Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-620
• 7 Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-1056
• 8 Hart R, Bate I, Dinh D. et al The detection of D-dimer in plasma by enzyme immunoassay: Improved discrimination is obtained with a more specific signal antibody. Blood Coag Fibrinol 1994; 5: 227-232
• 9 Eisenberg PR, Jaffe AS, Stump DC, Collen D, Bovill EG. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis. Circulation 1990; 82: 1159-1168
• 10 von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogenes. Acta Haematol (Basel) 1957; 17: 237-246
• 11 Abendschein DR, Ellis AK, Eisenberg PR, Klocke FJ, Sobel BE, Jaffe AS. Prompt detection of coronary recanalization by analysis of rates of change of concentrations of macromolecular markers in plasma. Cor Art Dis 1991; 2: 201-212
• 12 Lawler CW, Bovill EG, Stump DC, Collen D, Mann KG, Tracy RP. Fibrin fragment D-dimer and fibrinogen Bβ peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. Blood 1990; 76: 1341-1348
• 13 Salvioni A, Marenzi GC, Agostoni P, Grazi S, Guazzi MD. Influence of heparin on fibrinogen and D-dimer plasma levels in acute myocardial infarction treated with streptokinase. Eur Heart J 1994; 15: 654-659
• 14 Eisenberg PR, Galvani M, Ferrini D, Ottani F, Rusticali F, Abendschein D. Importance of assay specificity in interpretation of cross-linked fibrin degradation in patients treated with fibrinolytic agents. Fibrinolysis 1994; 8: 4 (A)
• 15 Francis CW, Doughney KB, Brenner B, Klingbiel K, Marder VJ. Increased reactivity of plasma after fibrinolytic activation in an anti-DD ELISA system: Role of soluble crosslinked fibrin polymers. Circulation 1989; 79: 666-673
• 16 Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen. Biochemistry 1986; 25: 4033-4040
• 17 Haskel EJ, Eisenberg PR, Abendschein DR. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood. Blood Coag Fibrinol 1993; 4: 7-13
• 18 Weitz JI, Kuint J, Leslie B, Hirsch J. Standard and low molecular weight heparin have no effect on tissue plasminogen activator induced plasma clot lysis of fibrinogenolysis. Thromb Haemost 1991; 65: 541-544
• 19 ISIS-3 (Third International Study on Infarct Survival) Collaborative Group. ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770
• 20 Gruppo italiano per lo studio della sopravvivenza nell’infarto miocardico. GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71
• 21 TIMI-9 Investigators (presented at the American Heart Association Sessions, Anaheim, CA, November 1995).